[A cross-sectional case study of human immunodeficiency virus and tuberculosis co-infection in mainland China].
OBJECTIVE
In order to take an insight into the profile of HIV/AIDS and tuberculosis (TB) co-infection, we made a statistic survey in 9 hospitals in mainland China. With the purpose of guiding the prevention and treatment, 241 cases with such co-infection were enrolled and the data with respect to clinical manifestations, laboratory tests, therapy and prognosis were analysed.


METHODS
All indices were collected with unified questionary.


RESULTS
Young men (75.9%) took constituted the majority. HIV was transmitted mainly by intravenous drug use (IDU) in Xinjiang and Yunnan provinces, by blood transfusion or blood products in Shanghai, Henan and Wenxi county of Shanxi, and by sexual transmission in Fuzhou, Shanghai, Shenzhen and Dehong prefecture of Yunnan province. In this survey, pulmonary TB accounted for 59.3%, extra-pulmonary TB for 21.2%, and both for 19.5% of the patients. As for laboratory tests, only 9.5% was positive in sputum for acid-fast bacillus (AFB) and 2.9% in culture, 10.8% of the patients had AFB in pleural fluid or cerebrospinal fluid. Besides, PPD was negative or weakly positive in most of the cases. Overall, 76.8% of the 241 cases had a CD(4) cell count < 200/microl, and 58.5% < 100/microl. 80.5% of the patients was treated with anti-tuberculous medications and 69.7% with highly active antiretroviral therapy (HAART). 203 (84.2%) were still alive and 38 (15.8%) died.


CONCLUSIONS
(1) The clinical manifestations of the 241 cases were varied because of prevailing pulmonary TB. (2) The immune function was depressed with reducing CD(4) counts in most of the patients. (3) Positivity rate of examination relevant to TB was too low to help the diagnosis. (4) The mortality (15.8%) was high even with HAART and/or chemotherapy.
Lu
Hong-zhou
HZ
Shanghai Public Health Center, Fudan University, Shanghai 201508, China. luhongzhou@fudan.edu.cn
Zhang
Yue-xin
YX
Zhou
Zeng-quan
ZQ
Ye
Han-hui
HH
Zhao
Qing-xia
QX
Wang
Hui
H
Wang
Fu-xiang
FX
Jia
Wang-qian
WQ
Sun
Hong-qing
HQ
Jiang
Xue-yan
XY
Ding
Li-min
LM
Su
Yan
Y
He
Yun
Y
Maimaitiaili
Wubuer
W
Yibaguli
Aibaidoula
A
Sun
Xiao-feng
XF
Liu
Bao-rong
BR
Hu
Ya-dong
YD
Tang
Wei
W
Zhou
Bo-ping
BP
Cao
Yun-zhen
YZ
D000163:Acquired Immunodeficiency Syndrome / Q000453:epidemiology*; D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D002681:China / Q000453:epidemiology; D015897:Comorbidity; D003430:Cross-Sectional Studies; D005260:Female; D015658:HIV Infections / Q000453:epidemiology*; D006801:Humans; D008297:Male; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D011379:Prognosis; D014376:Tuberculosis / Q000188:drug therapy / Q000453:epidemiology*
D000995:Antitubercular Agents